aTyr Pharma (NASDAQ:LIFE) Stock Price Crosses Above 200 Day Moving Average of $1.54

Shares of aTyr Pharma, Inc. (NASDAQ:LIFE) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.54 and traded as high as $1.70. aTyr Pharma shares last traded at $1.61, with a volume of 359,600 shares trading hands.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of aTyr Pharma in a research note on Friday, March 15th. Royal Bank of Canada decreased their price target on aTyr Pharma from $19.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, March 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, aTyr Pharma presently has a consensus rating of “Hold” and an average target price of $23.67.

aTyr Pharma Stock Performance

The company has a debt-to-equity ratio of 0.02, a current ratio of 6.27 and a quick ratio of 6.27. The stock has a market capitalization of $109.38 million, a PE ratio of -1.68 and a beta of 1.25. The stock has a 50 day moving average of $1.85 and a two-hundred day moving average of $1.54.

aTyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). Research analysts expect that aTyr Pharma, Inc. will post -0.97 EPS for the current fiscal year.

Hedge Funds Weigh In On aTyr Pharma

Hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC raised its holdings in aTyr Pharma by 5.1% during the third quarter. FMR LLC now owns 8,556,925 shares of the biotechnology company’s stock worth $13,520,000 after purchasing an additional 413,162 shares during the last quarter. Pale Fire Capital SE acquired a new position in aTyr Pharma during the third quarter worth $88,000. Virtu Financial LLC acquired a new position in aTyr Pharma during the first quarter worth $70,000. Charles Schwab Investment Management Inc. raised its holdings in aTyr Pharma by 166.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 26,689 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 16,689 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new position in aTyr Pharma during the third quarter worth $44,000. 61.72% of the stock is owned by institutional investors and hedge funds.

aTyr Pharma Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.